News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Generex Biotechnology Corporation (GNBT) / Antigen Express, Inc. (GNBT) To Participate In BioPharm America™ 2014



9/3/2014 9:09:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WORCESTER, Mass. and TORONTO, Sept. 3, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be participating in the 7th Annual International Partnering Conference BioPharm America 2014 being held September 22-24 in Boston. The conference is a significant business development forum for companies like Antigen Express, providing access to high-level executives and influential decision makers who attend the forum to liaise with key players in the industry, form partnerships, and evaluate emerging technologies. Antigen Express launched its strategic partnering program at the BIO International Convention in San Diego in June, 2014.

To get in touch with Antigen Express delegates at this event, please contact Dr. Eric von Hofe, Ph.D., President of Antigen Express (evonhofe@antigenexpress.com; 508-852-8783). The Company is in late Phase II development of a novel cancer immunotherapeutic to prevent relapse in patients who have had breast cancer.

"We are pleased with the reception the Antigen Express technologies and clinical trial data received earlier this year at the ASCO Annual Meeting in Chicago and at BIO in San Diego," commented Generex CEO Mark Fletcher. "We look forward to expanding and reinforcing partnering opportunities for our technologies at BioPharm in Boston."

About BioPharm America

BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, the world's leading web-based partnering system for the life science industry, BioPharm America is the only event in North America based on the same reputable formula as EBD Group's acclaimed European events BIO-Europe® and BIO-Europe Spring®.

http://www.ebdgroup.com/bpa/index.php

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.comor the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES